Phaseline

Companies › UroGen Pharma

UroGen Pharma: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 3, 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UGN-104
Mitomycin in thermally responsive hydrogel for intrapelvic instillation
–Phase 3Upper Urinary Tract Urothelial CarcinomaMar 2027
UGN-102
Mitomycin-hydrogel intravesical solution; mitomycin is a DNA alkylating agent
SLC23A2Phase 3Bladder CancerMar 2028
UGN-103
Mitomycin delivered via intravesical thermosensitive hydrogel
MITOMYCINPhase 3Bladder Cancer–
UGN-501
unclear - intravesical biologic for NMIBC
–Phase 1Bladder (Urothelial, Transitional Cell) CancerAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06331299UGN-103Phase 3Bladder CancerOncologySep 2025
NCT06774131UGN-104Phase 3Upper Urinary Tract Urothelial CarcinomaOncologyMar 2027
NCT05243550UGN-102Phase 3Bladder CancerOncologyMar 2028
NCT07725796UGN-501Phase 1Bladder (Urothelial, Transitional Cell) CancerOncologyAug 2029

From the company's SEC filings

Cash and short-term investments of $90m on 2026-09-30; operating cash outflow about $125m a year; runway about 9 months at that burn, to Jun 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SLC23A2 (1) MITOMYCIN (1)

Companies with the same targets

–

Companies built like this

Aura Biosciences Can-Fite BioPharma LeonaBio RenovoRx Verastem

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.